EMA Accepts First Diabetes Drug Onto PRIME
Hemophilia A Gene Therapy & DLBCL CAR-T Also Make The Grade
Executive Summary
Provention Bio’s teplizumab, a potentially game-changing treatment for preventing or delaying type 1 diabetes, is one of three investigational products to be newly accepted onto the European Medicines Agency’s popular priority medicines scheme.